SubQ-Sim: A Subcutaneous Physiologically Based Biopharmaceutics Model. Part 1: The Injection and System Parameters.
PBBM
back-flow
backpressure
depot
injection
modeling and simulation
physiology
subcutaneous
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
03
05
2023
accepted:
13
07
2023
medline:
5
10
2023
pubmed:
27
8
2023
entrez:
27
8
2023
Statut:
ppublish
Résumé
To construct a detailed mechanistic and physiologically based biopharmaceutics model capable of predicting 1) device-formulation-tissue interaction during the injection process and 2) binding, degradation, local distribution, diffusion, and drug absorption, following subcutaneous injection. This paper is part of a series and focusses on the first aspect. A mathematical model, SubQ-Sim, was developed incorporating the details of the various substructures within the subcutaneous environment together with the calculation of dynamic drug disposition towards the lymph ducts and venous capillaries. Literature was searched to derive key model parameters in healthy and diseased subjects. External factors such as body temperature, exercise, body position, food or stress provide a means to calculate the impact of "life events" on the pharmacokinetics of subcutaneously administered drugs. The model predicts the tissue backpressure time profile during the injection as a function of injection rate, volume injected, solution viscosity, and interstitial fluid viscosity. The shape of the depot and the concentrations of the formulation and proteins in the depot are described. The model enables prediction of formulation backflow following premature needle removal and the resulting formulation losses. Finally, the effect of disease (type 2 diabetes) or the presence of recombinant human hyaluronidase in the formulation on the injection pressure, are explored. This novel model can successfully predict tissue back pressure, depot dimensions, drug and protein concentration and formulation losses due to incorrect injection, which are all important starting conditions for predicting drug absorption from a subcutaneous dose. The next article will describe the absorption model and validation against clinical data.
Identifiants
pubmed: 37634241
doi: 10.1007/s11095-023-03567-0
pii: 10.1007/s11095-023-03567-0
pmc: PMC10547635
doi:
Substances chimiques
Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2195-2214Informations de copyright
© 2023. The Author(s).
Références
Diabetes Technol Ther. 2010 Aug;12(8):587-90
pubmed: 20615098
Int J Pharm. 2019 Jan 10;554:376-386
pubmed: 30414478
AAPS J. 2016 Jan;18(1):156-70
pubmed: 26408308
J Diabetes Sci Technol. 2016 Jun 28;10(4):914-22
pubmed: 26798083
Microcirculation. 1997 Jun;4(2):211-32
pubmed: 9219215
Pharm Res. 2015 Jul;32(7):2229-40
pubmed: 25537343
Pharm Res. 2021 Apr;38(4):607-624
pubmed: 33811278
Mayo Clin Proc. 2003 May;78(5):603-12
pubmed: 12744548
Circulation. 1990 Aug;82(2):465-72
pubmed: 2372894
Diabetes. 1989 Jul;38(7):819-24
pubmed: 2737363
J Invest Dermatol. 1994 May;102(5):807-11
pubmed: 8176267
Expert Opin Drug Deliv. 2021 Nov;18(11):1673-1685
pubmed: 34585991
Physiol Rev. 2012 Jul;92(3):1005-60
pubmed: 22811424
J Appl Toxicol. 2010 Jul;30(5):437-49
pubmed: 20186885
Scand J Clin Lab Invest. 1980 Apr;40(2):135-8
pubmed: 7256181
Front Immunol. 2020 May 19;11:769
pubmed: 32508807
J Physiol. 2014 Mar 15;592(6):1213-23
pubmed: 24421350
Diabetes Care. 1982 Mar-Apr;5(2):77-91
pubmed: 6765510
Diabetes. 2011 Jan;60(1):47-55
pubmed: 20943748
Diabetes Educ. 1991 Mar-Apr;17(2):90
pubmed: 1995285
Am J Physiol Endocrinol Metab. 2011 Oct;301(4):E659-67
pubmed: 21750269
Pediatr Res. 2021 Nov;90(5):963-965
pubmed: 33504969
Biochem J. 1986 Jun 1;236(2):521-5
pubmed: 3753464
Q J Exp Physiol. 1987 Oct;72(4):409-37
pubmed: 3321140
Clin Phys Physiol Meas. 1989 Aug;10(3):187-217
pubmed: 2697487
Diabetes Technol Ther. 2013 Apr;15(4):289-94
pubmed: 23427865
Pflugers Arch. 1976 Jun 22;363(3):231-4
pubmed: 986609
J Clin Invest. 2009 Dec;119(12):3502-11
pubmed: 19955661
Toxicol In Vitro. 2008 Mar;22(2):457-67
pubmed: 17981004
Am J Physiol. 1989 Jan;256(1 Pt 1):E12-8
pubmed: 2536230
Sci Rep. 2017 Aug 29;7(1):9613
pubmed: 28852051
Ann ICRP. 2002;32(3-4):5-265
pubmed: 14506981
Circulation. 1999 Jul 13;100(2):164-70
pubmed: 10402446
Pharm Res. 2021 Jun;38(6):1011-1030
pubmed: 34080101
AIDS Patient Care STDS. 2002 Jul;16(7):327-35
pubmed: 12194730
Int J Biol Macromol. 1994 Jun;16(3):137-42
pubmed: 7981160
Int J Obes (Lond). 2014 Aug;38(8):1019-26
pubmed: 24166067
Physiol Rep. 2017 Feb;5(3):
pubmed: 28174344
Physiol Rev. 2012 Jan;92(1):157-91
pubmed: 22298655
J Physiol. 1988 Oct;404:1-29
pubmed: 3075669
Pharm Res. 1998 Feb;15(2):254-62
pubmed: 9523312
J Pharm Sci. 2016 Jul;105(7):2105-13
pubmed: 27287520
Matrix Biol. 2019 Jul;80:46-58
pubmed: 30196101
Anal Biochem. 2015 Jul 1;480:74-81
pubmed: 25866075
J Pharm Pharm Sci. 2018;21(1s):130s-148s
pubmed: 30011390
Annu Rev Med. 2019 Jan 27;70:137-150
pubmed: 30355266
Cancer Res. 1974 Oct;34(10):2814-22
pubmed: 4369924
Diabetes Obes Metab. 2014 Oct;16(10):971-6
pubmed: 24720741
J Diabetes Sci Technol. 2012 Mar 01;6(2):389-93
pubmed: 22538152
Annu Rev Biomed Eng. 2007;9:229-56
pubmed: 17459001
Circulation. 1992 Apr;85(4):1457-63
pubmed: 1555286
Curr Opin HIV AIDS. 2020 Jan;15(1):33-41
pubmed: 31764198
J Pharmacol Toxicol Methods. 2013 May-Jun;67(3):140-7
pubmed: 23376811
PLoS One. 2018 Mar 29;13(3):e0195010
pubmed: 29596514
J Diabetes Sci Technol. 2013 Jan 01;7(1):227-37
pubmed: 23439181
Scand J Clin Lab Invest. 1973 Oct;32(2):167-73
pubmed: 4768303
Physiol Rev. 1994 Jan;74(1):163-219
pubmed: 8295933
Pharm Res. 2020 Feb 10;37(3):51
pubmed: 32043171
Microvasc Res. 1994 May;47(3):318-28
pubmed: 8084298